高血压药物的不良反应与药物基因组学关系的研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (10): 1183-1188.

高血压药物的不良反应与药物基因组学关系的研究进展

陶然¹, 黄红光¹, 高利臣²

¹ 南华大学长沙市中心医院心内科,
² 药学部, 长沙 410004,湖南

收稿日期:2014-02-22 修回日期:2014-08-13 出版日期:2014-10-26 发布日期:2014-10-29
通讯作者: 黄红光, 女, 教授, 硕士生导师,研究方向:心血管疾病临床研究。E-mail: huanghongguangcn@yahoo.com.cn
作者简介:陶然, 女, 硕士,研究方向:心血管疾病临床研究。E-mail: 1287110127@qq.com
基金资助:
湖南省医药卫生科研计划课题(B2007173)

Advances in pharmacogenomics research of adverse effects of hypertension therapy drugs

TAO Ran¹, HUANG Hong-guang¹, GAO Li-chen²

¹ Department of Cardiology, Changsha Central Hospital, University of South China;
² Department of Pharmacy, Changsha Central Hospital, Changsha 410004, Hunan, China

Received:2014-02-22 Revised:2014-08-13 Online:2014-10-26 Published:2014-10-29

摘要/Abstract

摘要： 近来,个体差异造成降压药物不良反应的不同越来越受到重视,通过药物基因组学的研究,基因多态性已被认为是造成药物不良反应的首要原因。从基因水平揭示高血压药物不良反应的个体差异是一种有效的方法。本文综述了常用降压药物的不良反应与药物基因组学关系的研究进展,为高血压药物个体化应用于临床治疗应用提供参考依据。

关键词: 高血压, 药物, 不良反应, 药物基因组学

Abstract: Recently, increasingly importance has been attached to antihypertensive drug side effects caused by individual differences.According to the research of pharmacogenomics,genetic polymorphisms have been considered to be the primary cause of adverse drug reactions .From the level of gene revealed individual differences of adverse reactions to antihypertensive drugs is an effective method. This review summarized the research progress of the relationship between the adverse reactions to antihypertensive drugs and genetic polymorphisms.

Key words: hypertension, drugs, adverse effects, pharmacogenomics

中图分类号:

R968

陶然, 黄红光, 高利臣. 高血压药物的不良反应与药物基因组学关系的研究进展[J]. 中国临床药理学与治疗学, 2014, 19(10): 1183-1188.

TAO Ran, HUANG Hong-guang, GAO Li-chen. Advances in pharmacogenomics research of adverse effects of hypertension therapy drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1183-1188.

参考文献 29

[1]	Kassan M, Wecker A, Kadowitz P, et al.C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml1-1009-2501-19-10-1183"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula>C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml2-1009-2501-19-10-1183"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>25</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula>Foxp3 regulatory T cells and vascular dysfunction in hypertension[J].J Hypertens, 2013,31(10):1939-1943.
[2]	中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 血管紧张素转换酶抑制剂在心血管病中应用中国专家共识[J]. 中华心血管病杂志,2007,35(2): 97-106.
[3]	Kim TB,Oh SY,Park HK,et al.Polymorphisms in the neurokinin-2 receptor gene are associated with angiotensin-converting enzyme inhibitor-induced cough[J]. J Clin Pharm Ther,2009,34(4):457-464.
[4]	Nishio K, Kashiki S, Tachibana H,et al.Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis[J]. World J Cardiol, 2011, 3(10): 329-336.
[5]	Furuya K, Yamaguchi E, Hirabayashi T,et al.Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough[J]. Lancet, 1994,343(8893):354.
[6]	Sarkar P, Nicholson G, Hall G.Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications[J]. Can J Anaesth,2006, 53(10), 994-1003.
[7]	Cilia La Corte AL, Carter AM, Rice GI,et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema[J]. Hum Mutat,2011 ,32(11):1326-1331.
[8]	Schelleman HK, Witteman OH, Breteler JC, et al.Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers[J]. Eur J Hum Genet, 2007,15(4):478-484.
[9]	Flora DR, Tracy TS.Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator[J]. Drug Metab Dispos,2012,40(4):836-842.
[10]	Chen RN, Ho HO, Yu CY,et al.Development of swelling /floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism[J]. Eur J Pharm Sci,2010,39(1/2/3):82-89.
[11]	Choi CI, Kim MJ, Chung EK,et al.CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects[J]. Eur J Clin Pharmacol,2012, 68(2):149-154.
[12]	Barone C, Mousa SS, Mousa SA.Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascularmedicine[J]. Pharmgenomics Pers Med,2009,2:59-67.
[13]	中华医学会心血管病学分会,中华心血管病杂志编辑委员会. β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J]. 中华心血管病杂志,2009,37(3): 195-209.
[14]	Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines[J]. Clin Pharmacol Ther,2011,89(5):662-673.
[15]	Samer CF, Lorenzini KI, Rollason V, et al.Applications of CYP450 testing in the clinical setting[J]. Mol Diagn Ther,2013,17(3):165-184.
[16]	Jin SK, Chung HJ, Chung MW,et al.Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy korean volunteers[J]. J Clin Pharm Ther,2008, 33(5):567-573.
[17]	Petersen M, Andersen JT, Hjelvang BR,et al.Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failurepatients[J].Br J Clin Pharmacol, 2011,71(4):556-565.
[18]	Lanfear DE, Jones PG, Marsh S,et al.Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome[J].JAMA, 2005,294(12):1526-1533.
[19]	Iaccarino G, Trimarco V, Lanni F,et al.beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene[J]. Pharmacogenomics J,2005,5(5):292-297.
[20]	McDonough CW, Gillis NK, Alsultan A,et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study[J]. PLoS One, 2013, 8(10): e76984.
[21]	Beitelshees AL, Gong Y, Wang D,et al.KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)[J]. Pharmacogenet Genomics,2007,17(9):719-729.
[22]	Niu Y, Gong Y, Langaee TY,et al.Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)[J]. Circ Cardiovasc Genet, 2010,3(6):548-555.
[23]	Levy D, Ehret GB, Rice K,et al.Genome-Wide association study of blood pressure and hypertension[J].Nat Genet,2009,41(6):677-687.
[24]	The ALLHAT officers and coordinators for the ALLHAT collaborative research group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT )[J].JAMA, 2002, 288(23):2981-2997.
[25]	Turner ST, Bailey KR, Fridley BL,et al.Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic[J].Hypertension,2008,52(2):359-365.
[26]	Karnes JH, Gong Y, Pacanowski MA, et al.Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes[J]. Pharmacogenet Genomics, 2013,23(12):697-705.
[27]	Karnes JH, McDonough CW, Gong Y, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment[J]. Pharmacogenomics J,2013 Oct,13(5):430-436.
[28]	Grant SF, Thorleifsson G, Reynisdottir I,et al.Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes[J]. Nat Genet,2006,38(3):320-323.
[29]	李镒冲,王丽敏,姜勇,等.2010年中国成年人高血压患病情况[J].中华预防医学杂志,2012,26(5):409-413.